Vaccination to prevent mpox
BMJ 2024; 386 doi: https://doi.org/10.1136/bmj.q2057 (Published 23 September 2024) Cite this as: BMJ 2024;386:q2057Linked Research
Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial
- Nick Andrews, statistician,
- Sema Mandal, consultant epidemiologist
- UK Health Security Agency, London, UK
- Correspondence to: N Andrews nick.andrews{at}ukhsa.gov.uk
The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine, originally developed to protect against smallpox, was introduced in 2022 to help tackle the large mpox outbreak caused by the clade IIb virus, which by August of that year had affected a total of 30 000 people globally.1 The number of clade IIb infections was lower in 2023, but later that year the number of clade l infections started increasing in the Democratic Republic of the Congo. The emergence of a novel clade 1b virus in 2024 and the subsequent spread into neighbouring countries, led the World Health Organization to declare a new public health emergency of international concern.12
Understanding the effectiveness of vaccination to prevent mpox will determine how the vaccine can be used, along with other control measures, to limit spread. The linked paper by Navarro and colleagues (doi: …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.